Showing 1121-1130 of 1148 results for "".
- Detailed Results of Phase 3 Trials of Aducanumab for Alzheimer’s Disease Presentedhttps://practicalneurology.com/news/detailed-results-of-phase-3-trials-of-aducanumab-for-alzheimers-disease-presented/2469092/At the 12th Clinical Trials in Alzheimer’s Disease conference in San Diego, CA, detailed data from the EMERGE (NCT02484547) and ENGAGE (NCT02477800)clinical trials of
- Pimavanserin Reduce Risks of Dementia-Related Psychotic Relapse Almost Threefoldhttps://practicalneurology.com/news/pimavanserin-reduce-risks-of-dementia-related-psychotic-relapse-almost-threefold/2469089/In top-line results from the pivotal phase 3 HARMONY (NCT03325556) study, treatment with pimavanserin vs placebo (Nuplazid, Acadia Pharmaceuticals, San Diego, CA) reduced risk of psychotic relapse by 2.8 fold (HR = 0.353; one-sided
- Pimavanserin Also Effective as Adjunct Treatment for Major Depressive Disorderhttps://practicalneurology.com/news/pimavanserin-also-effective-as-adjunct-treatment-for-major-depressive-disorder/2469034/Approved for treatment of psychosis in Parkinson’s disease (PD) and with positive clinical trial results for treatment of psychosis in other forms of dementia, pimavanserin (Nuplazid; Acadia, Pharmaceuticals, San Diego, CA) may also be effective as adjunctive treatment for major depressive
- Combined Lifestyle Interventions May Offset Alzheimer’s Disease Riskshttps://practicalneurology.com/news/combined-lifestyle-interventions-may-offset-alzheimers-disease-risks/2468957/Research findings reported at the Alzheimer’s Association International Conference in Los Angeles, July 14-18, 2019 suggest that healthy lifestyle choices—including diet, exercise, and cognitive stimulation—may decrease risk of cognitive decline and dementia.
- Potential Treatment for Spinocerebellar Ataxia, CAD-1883, Granted Orphan Drug Statushttps://practicalneurology.com/news/potential-treatment-for-spinocerebellar-ataxia-cad-1883-granted-orphan-drug-status-1/2468913/The Food and Drug Administration (FDA) has granted orphan drug designation to CAD-1883 (Cadence Pharmaceuticals, San Diego, CA), an investigational treatment for spinocerebellar ataxia (SCA).The drug is also under investigation for treatment of essential tremor and other movement disorders.
- Opicapone Increases ON Time for Parkinson's Diseasehttps://practicalneurology.com/news/opicapone-increases-on-time-for-parkinsons-disease/2468886/In 2 phase 3 studies, treatment with opicapone (Neurocrine Biosciences, San Diego, CA) increased ON time without troublesome dyskinesia almost twice as much as placebo for participants with Parkinson’s disease (PD). The ON period was defined as the period during which motor symptoms are con
- Valbenazine Improvements for Tardive Dyskinesia Are Sustained in People Taking Different Neuropsychiatric Drugshttps://practicalneurology.com/news/valbenazine-improvements-for-tardive-dyskinesia-are-sustained-in-people-taking-different-neuropsychiatric-drugs/2468885/Pooled data analysis from 2 phase 3 trials shows that valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA), approved for treatment of tardive dyskinesia (TD) in adults, has sustained efficacy whether or not other neuropsychiatric drugs are taken concomitantly. The efficacy and safety of
- Minimally Invasive Removal of Deep Subcortical Hemorrhagehttps://practicalneurology.com/news/minimally-invasive-removal-of-deep-subcortical-hemorrhage/2468770/Minimally invasive techniques have been used to treat deep subcortical hemorrhages successfully. In 2 abstracts, presented at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in San Diego, CA, minimally invasive parafascicular surgery (MIPS) with tubular retracto
- Blood Test for TBI Licensed for Use and Development on Abbot Laboratory Instrumentshttps://practicalneurology.com/news/blood-test-for-tbi-licensed-for-use-and-develoment-on-abbot-laboratory-instruments/2468773/A Food and Drug Administration (FDA) approved blood test for mild traumatic brain injury (mTBI), also known as concussion, may become more widely available soon. The blood test (Banyan Brain Trauma Indicator; Banyan Biomarkers, San Diego, CA) has been licensed to Abbott Laboratories (Abbott Park,
- First Participant Dosed in Phase 2 Trial of Phosphodiesterase Inhibitor AR1001 for Alzheimer's Diseasehttps://practicalneurology.com/news/first-participant-dosed-in-phase-2-trial-of-phosphodiesterase-inhibitor-ar1001-for-alzheimers-disease/2468777/The first patient has been dosed in a phase 2 study evaluating safety and efficacy of AR1001 (AR1001; AriBio, San Diego, CA). A novel phosphodiesterase inhibitor, AR1001, is being investigated for treatment of Alzheimer’s disease (AD). The 26-week double-blind placebo-controlled stu